X4 Pharmaceuticals (XFOR) to Announce Quarterly Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $2.42 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.The company had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Stock Up 1.8%

XFOR stock opened at $4.00 on Thursday. The business has a 50 day moving average of $4.01 and a 200 day moving average of $3.93. The firm has a market cap of $377.28 million, a PE ratio of -0.88 and a beta of 0.35. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the transaction, the chief financial officer directly owned 167,750 shares of the company’s stock, valued at $714,615. This represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in XFOR. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals during the fourth quarter valued at $50,000. Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals in the third quarter worth about $47,000. Stifel Financial Corp bought a new position in shares of X4 Pharmaceuticals in the fourth quarter worth about $82,000. Virtu Financial LLC bought a new position in shares of X4 Pharmaceuticals during the 4th quarter valued at approximately $90,000. Finally, Man Group plc purchased a new stake in X4 Pharmaceuticals in the 4th quarter worth approximately $97,000. Institutional investors own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on XFOR. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Leerink Partners initiated coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target for the company. Finally, Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.70.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.